- Procedure started
- Under evaluation
- CHMP opinion
- European Commission final decision
On 23 April 2009, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Ciclosporin IDL. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Ciclosporin IDL do not outweigh its risks, and that the marketing authorisation granted in the Netherlands cannot be recognised in other Member States of the EU and that the marketing authorisation in the Netherlands should be suspended.
The company that markets Ciclosporin IDL, International Drug Licensing, requested a re-examination of the opinion. After having considered the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the recommendation for the refusal and suspension of the marketing authorisation on 23 July 2009.
The review was carried out under an 'Article 29' referral1.
A European Commission decision on this opinion will be issued in due course.
1 Article 29 of Directive 2001/83/EC as amended, referral on the grounds of potential serious risk to public health
About this medicine
|International non-proprietary name (INN) or common name||
About this procedure
European Commission final decision
Key dates and outcomes
|CHMP opinion date||
|EC decision date||
Questions and answers on the referral for Ciclosporin IDL and associated names capsules containing ciclosporin 25 mg, 50 mg and 100 mg - Re-examination (PDF/118.34 KB)Adopted
First published: 23/07/2009
Last updated: 20/11/2013
Questions and answers on the referral for Ciclosporin IDL and associated names capsules containing ciclosporin 25 mg, 50 mg and 100 mg - Initial (PDF/33.27 KB)Adopted
First published: 23/04/2009
Last updated: 23/04/2009
Ciclosporin IDL - Article-30 referral - Annex I, II, III (PDF/44.33 KB)
First published: 20/11/2013
Last updated: 20/11/2013
Description of documents published
Please note that some of the listed documents apply only to certain procedures.
- Overview - lay-language summary of the stage of the procedure
- Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
- Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
- List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
- Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
- List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
- List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
- Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
- Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
- Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
- Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
- Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
- Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
- Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
- Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)
Note that older documents may have different titles.